Comparing EU MDR with Other Markets: Five Dimensions That Differ

1. Key takeaways

Differences in regulatory structure across markets concentrate in five dimensions: classification systems, the names of local entity roles, the form of validity, vigilance deadlines and the form of quality management system evidence. The European Union follows the path of classification, then conformity assessment, then the EU declaration of conformity plus CE marking plus EUDAMED registration; foreign entities connect through the EU authorised representative (EC REP). The EU route is not a matter of applying to a government for a single registration certificate.

The consequence for multinational programmes is that nothing transfers automatically between markets: not the class, not the role names, not the renewal calendar and not the vigilance timers. Each market must be managed against its own rules, with a comparison matrix as the controlling document.

The comparison is most useful when it is written down as a table per product line, with one column per market and the fifth dimension, quality management system evidence, described by the certificate that each market actually requires. Once the matrix exists, every new market entry becomes a filling exercise rather than a research project, and every regulatory change in one market can be checked against the other dimensions for knock-on effects.

2. Legal basis

The EU-side provisions referenced below are drawn from Regulation (EU) 2017/745, as amended, and from the separate IVD regulation.

3. Expert insights

Insight 1: Classification systems do not transfer, and cross-market inference fails.

The European Union uses four classes, I, IIa, IIb and III, determined under the 22 rules of Annex VIII; most Southeast Asian markets use A/B/C/D or other local gradings; the United States uses Class I, II and III; Canada uses Class I to IV. The class of the same product must be determined separately in each market, and an inference such as the device is class B in one market therefore class IIa in the EU does not hold. Classification teams should work from the rule sets of each jurisdiction rather than from translations between them.

Insight 2: The names and responsibilities of local entity roles differ widely.

The EU EC REP (Article 11) carries verification, document retention and cooperation duties and is jointly liable where the manufacturer fails its obligations under Article 10 (Article 11(5)); the EU importer (Article 13) carries pre-placement verification duties. The License Holder of several Southeast Asian markets is usually the holder of the registration certificate, a different legal construct. The United States corresponds to the US Agent and the initial importer; Canada corresponds to importers and distributors under the Medical Device Establishment Licence (MDEL) system. The role names of the four markets must not be used interchangeably in documents or in contracts. The safest convention is to give the official local title first in every document, with the internal shorthand only in brackets, so that contracts and filings never depend on informal naming.

Insight 3: The numbers of vigilance deadlines differ, and one shared calendar does not work.

In the EU, Article 87 tiers the deadlines by consequence into 15 days, 10 days and 2 days, with periods calculated under Regulation (EEC, Euratom) No 1182/71; other markets have their own deadlines and their own start points. The vigilance systems of multinational companies must be configured with deadline rules per market, rather than applying the fastest tier uniformly across the world. A single global timer is both over-compliant in some markets and non-compliant in others.

Insight 4: The form of validity and renewal differs by market.

EU CE certificates are issued by notified bodies with a validity period, and Article 120(3a) adds transitional arrangements for legacy certificates (2027-12-31 / 2028-12-31); several Southeast Asian markets use registration certificates with renewal cycles; a US 510(k) has no expiry date but carries change and annual reporting duties; Canada uses a medical device licence (MDL) with an annual licence review. The form of validity is the item most easily assumed to be consistent in multinational project management and yet the most divergent in reality (a practical estimate). A quarterly reconciliation of the validity ledger against the actual certificates and registrations catches the drift that otherwise appears after two or three renewal cycles.

Insight 5: In vitro diagnostic devices follow the separate IVDR in the EU.

In vitro diagnostic medical devices are governed by Regulation (EU) 2017/746 (IVDR), applicable from 2022-05-26, with classification, transitional periods and pathways that all differ from the MDR. Companies whose product lines contain both devices and IVDs must manage the two under separate regulatory tracks, including separate compliance ledgers and separate transition planning.

4. Practical recommendations

The measures below turn the comparison into standing administrative practice rather than a one-time study.

1. Build a market by five dimensions comparison matrix (classification, local entities, form of validity, vigilance deadlines, QMS evidence form) and maintain it per market.
2. Use the locally statutory entity names in the local documents of each market; do not substitute equivalents across markets.
3. Configure the vigilance system with independent deadline rules and time zone and calendar rules per market.
4. Keep validity ledgers separately per market and do not share renewal reminders between jurisdictions.
5. Maintain separate compliance ledgers for device and IVD product lines under the MDR and the IVDR respectively.

5. Verification checklist

Use the checklist below whenever a new market is added or a renewal cycle is planned.

• □ A market by five dimensions comparison matrix has been established
• □ Local statutory entity names are used in the documents of each market
• □ Vigilance deadline rules are configured independently per market
• □ Validity ledgers are maintained separately per market
• □ Legacy device transition deadlines (2027-12-31 / 2028-12-31) are included in the EU ledger
• □ Device and IVD lines have separate ledgers under the MDR and the IVDR

Regulatory information verified as of 29 October 2026.

GRZAN regulatory support. GRZAN assists medical device manufacturers with post-market compliance in the European Union market under Regulation (EU) 2017/745, covering vigilance reporting, field safety corrective action (FSCA) recalls, and responses to competent authority inspections, as well as cross-market comparison and coordination. If you need support with your EU MDR post-market obligations, contact info@grzanglobal.com.